ICCC Q1 2020 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+11.3% YoY

Gross Profit

$2M45.5% margin

Operating Income

$196,8774.0% margin

Net Income

-$122,267-2.5% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+35.2%

Cash Flow

Operating Cash Flow

$857,453

Free Cash Flow

-$394,694

Stock-Based Comp.

$77,404

Balance Sheet

Total Assets

$40M

Total Liabilities

$11M

Stockholders' Equity

$29M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$4M	+11.3%
Gross Profit	$2M	$2M	+1.6%
Operating Income	$196,877	$265,304	-25.8%
Net Income	-$122,267	$144,555	-184.6%